New study checks safety of clotting drug in indian hemophilia patients

NCT ID NCT07446010

Not yet recruiting Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Mar 07, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This study looks at the safety and real-world use of Octocog alfa, a lab-made clotting factor, for treating bleeding episodes in adults with severe hemophilia A in India. About 33 people who have used factor VIII before will receive the drug on-demand when they have a bleed. Researchers will track side effects and how well the treatment works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • All India Institute Of Medical Sciences

    New Delhi, India

  • Christian Medical College & Hospital

    Ludhiana, India

  • Department of Medicine Assam Medical College & Hospital

    Dibrugarh, India

  • Government of Medical College Kozhikode

    Kozhikode, India

  • Sahyadri Super Speciality Hospital

    Pune, India

  • Sanjay Gandhi Post Graduate Institute & Medical Sciences

    Lucknow, India

Conditions

Explore the condition pages connected to this study.